{
    "clinical_study": {
        "@rank": "164869", 
        "acronym": "SANE", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This local, prospective, multicenter, non-interventional study documents observational data\n      on patients under routine treatment of metastatic RCC with Nexavar before and after\n      cytoreductive nephrectomy. It's planned to better understand the impact of cytoreductive\n      nephrectomy on Nexavar efficacy and possibly to define patients who get the most benefit\n      from Nexavar before cytoreductive nephrectomy."
        }, 
        "brief_title": "Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Renal Cell", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  - Male and female patients \u2265 18 years old\n\n          -  Patients with untreated metastatic RCC in whom a decision on neoadjuvant treatment\n             with Nexavar before cytoreductive nephrectomy and in case of clinical feasibility\n             resumption of treatment with Nexavar after nephrectomy has been made at the time of\n             study enrollment\n\n          -  Life expectancy of at least 16 weeks\n\n          -  Patients should have signed informed consent form\n\n        Exclusion Criteria:\n\n          -  Diagnosis of any second malignancy within the last 5 years, except for adequately\n             treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer.\n\n          -  All contra-indications according to the Russian marketing authorization:\n\n               -  Hypersensitivity to sorafenib or to any of the excipients.\n\n               -  Pregnancy and breast-feeding.\n\n               -  Age less than 18 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male and female patients \u2265 18 years old with untreated metastatic RCC for whom treatment\n        with Nexavar is planned with subsequent cytoreductive nephrectomy and resumption of\n        Nexavar in case of clinical feasibility"
            }
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982097", 
            "org_study_id": "16933", 
            "secondary_id": "NX1307RU"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.", 
            "intervention_name": "Sorafenib (Nexavar, BAY 43-9006)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-interventional", 
            "Nexavar", 
            "Sorafenib", 
            "Carcinoma, renal cell", 
            "Neoadjuvant", 
            "Nephrectomy", 
            "Russian Federation"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Russian Federation"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Multicenter, Prospective, Non-interventional Study \"Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma\"", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russian Federation: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum percent reduction (based on the minimum post baseline value) in the longest diameter of the primary tumor in response to neoadjuvant Nexavar treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Response rate of residual disease to Nexavar according to RECIST 1.1 with baseline after cytoreductive nephrectomy.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982097"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response before cytoreductive nephrectomy according to RECIST 1.1.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Maximum percent reduction in the sum of longest diameters of target lesions according to RECIST 1.1 while on Nexavar treatment before cytoreductive nephrectomy", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Maximum percent reduction in the sum of longest diameters of target lesions of residual disease after cytoreductive nephrectomy according to RECIST 1.1 while on Nexavar treatment with baseline after cytoreductive nephrectomy.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Number of participants with AEs, including intra- and postoperative complications, relation to Nexavar treatment, AEs treatment, AEs outcome.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}